Language:

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

The New England journal of medicine, 2015-03, Vol.372 (13), p.1193-1203 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Copyright © 2015 Massachusetts Medical Society. 2015 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414264 ;PMID: 25692915

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Author: Wells, John A ; Glassman, Adam R ; Ayala, Allison R ; Jampol, Lee M ; Aiello, Lloyd Paul ; Antoszyk, Andrew N ; Arnold-Bush, Bambi ; Baker, Carl W ; Bressler, Neil M ; Browning, David J ; Elman, Michael J ; Ferris, Frederick L ; Friedman, Scott M ; Melia, Michele ; Pieramici, Dante J ; Sun, Jennifer K ; Beck, Roy W
Subjects: Acuity ; Adult ; Aged ; Angiogenesis Inhibitors - administration & dosage ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Bevacizumab ; Clinical trials ; Diabetes ; Diabetes mellitus ; Diabetic retinopathy ; Diabetic Retinopathy - drug therapy ; Double-Blind Method ; Drug dosages ; Drug therapy ; Edema ; Eyes & eyesight ; Female ; Humans ; Immunotherapy ; Intravitreal Injections ; Macular Edema - drug therapy ; Male ; Middle Aged ; Monoclonal antibodies ; Ranibizumab ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Receptors, Vascular Endothelial Growth Factor - adverse effects ; Recombinant Fusion Proteins - administration & dosage ; Recombinant Fusion Proteins - adverse effects ; Retina - drug effects ; Retina - pathology ; Therapeutic Equivalency ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vision ; Visual Acuity - drug effects
Is Part Of: The New England journal of medicine, 2015-03, Vol.372 (13), p.1193-1203
Description: A trial of three drugs — bevacizumab, ranibizumab, and aflibercept — for the treatment of diabetic macular edema showed that each drug improved visual acuity, but aflibercept outperformed the other two drugs for eyes with a baseline visual acuity of 20/50 or worse. Diabetic macular edema, a manifestation of diabetic retinopathy that impairs central vision, affects approximately 750,000 people in the United States and is a leading cause of vision loss. 1 The costs associated with visual disability and treatment of diabetic macular edema are high. 2 The increasing prevalence of diabetes worldwide highlights the importance of diabetic macular edema as a global health issue. 3 Vascular endothelial growth factor (VEGF) is an important mediator of abnormal vascular permeability in diabetic macular edema. 4 , 5 Intravitreous injections of anti-VEGF agents have been shown to be superior to laser photocoagulation of the macula, the standard treatment for diabetic . . .
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1414264
PMID: 25692915
Source: ProQuest One Psychology
MEDLINE
Alma/SFX Local Collection
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Copyright © 2015 Massachusetts Medical Society. 2015 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414264 ;PMID: 25692915

Searching Remote Databases, Please Wait